The estimated Net Worth of Matthew C Kapusta is at least $31.5 Milión dollars as of 26 February 2024. Mr. Kapusta owns over 27,904 units of uniQure N.V stock worth over $2,411,389 and over the last 13 years he sold QURE stock worth over $24,379,698. In addition, he makes $4,719,960 as Chief Executive Officer, Chief Financial Officer a Executive Director at uniQure N.V.
Sign up
Mr. Kapusta QURE stock SEC Form 4 insiders trading
Matthew has made over 46 trades of the uniQure N.V stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 27,904 units of QURE stock worth $177,190 on 26 February 2024.
The largest trade he's ever made was selling 67,376 units of uniQure N.V stock on 13 March 2019 worth over $4,309,369. On average, Matthew trades about 8,416 units every 62 days since 2012. As of 26 February 2024 he still owns at least 440,839 units of uniQure N.V stock.
You can see the complete history of Mr. Kapusta stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Matthew Kapusta biography
Matthew Kapusta CPA serves as Chief Executive Officer, Chief Financial Officer, Executive Director of the Company. Mr. Kapusta also has served as our Chief Financial Officer since joining uniQure in January 2015. Prior to joining uniQure, Mr. Kapusta was Senior Vice President at AngioDynamics (NASDAQ: ANGO) from 2011 to 2014, responsible for corporate development, strategic planning and national accounts. Prior to AngioDynamics, he served as Vice President, Finance and Strategic Planning and Analysis for Smith & Nephew Orthopaedics. Mr. Kapusta’s career also includes more than a decade of investment banking experience focused on emerging life sciences companies. Mr. Kapusta was Managing Director, Healthcare Investment Banking at Collins Stewart, and held various positions at Wells Fargo Securities, Robertson Stephens and PaineWebber. Mr. Kapusta holds a Master of Business Administration from New York University’s Stern School of Business, a Bachelor of Business Administration from University of Michigan’s Ross School of Business and earned his Certified Public Accountant license in 1996 while at Ernst & Young.
What is the salary of Matthew Kapusta?
As the Chief Executive Officer, Chief Financial Officer a Executive Director of uniQure N.V, the total compensation of Matthew Kapusta at uniQure N.V is $4,719,960. There are no executives at uniQure N.V getting paid more.
How old is Matthew Kapusta?
Matthew Kapusta is 47, he's been the Chief Executive Officer, Chief Financial Officer a Executive Director of uniQure N.V since 2016. There are 15 older and no younger executives at uniQure N.V. The oldest executive at uniQure N.V. is Jack Kaye, 76, who is the Non-Executive Independent Director.
What's Matthew Kapusta's mailing address?
Matthew's mailing address filed with the SEC is C/O UNIQURE, N.V., , AMSTERDAM P7, , 11058BP.
Insiders trading at uniQure N.V
Over the last 8 years, insiders at uniQure N.V have traded over $35,572,573 worth of uniQure N.V stock. The most active insiders traders include Deventer Sander Van, Paula Soteropoulos a William Lewis. On average, uniQure N.V executives and independent directors trade stock every 14 days with the average trade being worth of $37,634. The most recent stock trade was executed by Walid Abi Saab on 26 June 2024, trading 1,447 units of QURE stock currently worth $6,309.
What does uniQure N.V do?
uniqure is delivering on the promise of gene therapy - single treatments with potentially curative results. we are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.
What does uniQure N.V's logo look like?
Complete history of Mr. Kapusta stock trades at Angiodynamic Inc a uniQure N.V
uniQure N.V executives and stock owners
uniQure N.V executives and other stock owners filed with the SEC include:
-
Matthew Kapusta,
Chief Executive Officer, Chief Financial Officer, Executive Director -
Robert Gut,
Executive Director -
Alexander Kuta,
Executive Vice President, Operations -
Maria Cantor,
Senior Vice President, Investor Relations and Communications -
Matthew Craig Kapusta,
CEO & Exec. Director -
Dr. Alexander E. Kuta Ph.D.,
Exec. VP of Quality & Regulatory -
Dr. Ricardo Dolmetsch Ph.D.,
Pres of R&D -
Christian Klemt,
CFO, Principal Financial Officer & GM of Amsterdam Site -
David Meek,
Non-Executive Independent Director -
Philip Astley-Sparke,
Independent Non-Executive Chairman of the Board -
Jack Kaye,
Non-Executive Independent Director -
Jeremy Springhorn,
Non-Executive Independent Director -
Madhavan Balachandran,
Non-Executive Independent Director -
Paula Soteropoulos,
Non-Executive Independent Director -
Leonard Post,
Director -
Ricardo Dolmetsch,
President, Research and Development -
Erin Boyer,
Chief People & Culture Office -
Richard Porter Ph.D.,
SVP of R&D and GM of Corlieve -
Dr. Tamara Tugal Ph.D., MBA,
Bus. Devel. Director -
Maria E. Cantor,
Chief Communications Officer -
David Cerveny,
Chief Legal Officer, Gen. Counsel & Sec. -
Pierre Caloz,
Chief Operating Officer -
Prof. Hugo Katus,
Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany -
Rachelle Suzanne Jacques,
Director -
Christian Meyer,
Chief Medical Officer -
Harald Petry,
Chief Scientific Officer -
Maiken Keson Brookes,
General Counsel -
Jonathan Garen,
Chief Business Officer -
David Schaffer,
Director -
Paul E Firuta,
Chief Commercial Officer -
William Lewis,
Director -
Steven Zelenkofske,
Chief Medical Officer -
Deventer Sander Van,
EVP, Research & Product Dev. -
Scott T. Mc Millan,
Chief Operating Officer -
Pierre Caloz,
Chief Operating Officer -
Christian Klemt,
Chief Financial Officer -
Jeannette Potts,
Chief Legal Officer -
Walid Abi Saab,
Chief Medical Officer